We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 520

The date is set - new trademark law will be in force June 2019
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 3 2018

After years of uncertainty, a date has been set for the implementation of Canada's new Trademark Law, which will come into force on 17 June 2019. The


Canada’s new Patent Rules: twelve notable changes and tips
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 3 2018

On December 1, 2018, the Canadian government released its proposed new Patent Rules in the Canada Gazette, Part I. This is one of the last steps


Anti-dilution remedy not limited to registered trademarks
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 3 2018

Section 22 of the Trademarks Act, depreciation of a registered trademark's goodwill, is a potentially powerful yet generally underused weapon for


Supreme Court of Canada Leave Applications
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 30 2018

Supreme Court of Canada denies Eli Lilly leave to appeal in olanzapine section 8 damages action. On November 8, 2018, Eli Lilly was denied


PMPRB amendments will likely not be implemented by January 2019
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 30 2018

We previously reported on proposed amendments to the Patented Medicines Regulationsreleased on December 2, 2017. The originally proposed coming


Common invalidity issues in FAMPYRA PMNOC actions against Taro and Apotex to be heard concurrently
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 30 2018

On October 16, 2018, Prothonotary Tabib ordered that common validity issues in actions relating to Biogen's fampridine (FAMPYRA) against Taro


Ontario Court of Appeal allows Sanofi and Schering to plead that Federal Court ramipril patent invalidity decision was flawed due to “promise doctrine”
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 29 2018

In an action by Apotex for compensation from Sanofi and Schering under the Ontario Statute of Monopolies, U.K. Statute of Monopolies and the


Divided success in Sandoz’s motion to strike monetary remedies and other novel claims in rituximab PMNOC actions
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 29 2018

A Federal Court Order has issued on a motion to strike brought by Sandoz in four actions relating to infringement of rituximab patents. The Court’s


CADTH releases Environmental Scan on International Policies on Use of Biosimilars
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 29 2018

In October 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued an interesting Environmental Scan on International Policies


Apotex not permitted to plead promise-based invalidity grounds in Section 8 lansoprazole action
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 19 2018

The Ontario Superior Court of Justice recently dismissed Apotex's motion to plead promise-based invalidity grounds in a Section 8 lansoprazole action